Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,559 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05264896RecruitingPhase 3
Stomach cancer surgery plus two chemo plans
This trial compares two chemotherapy schedules around stomach cancer surgery: giving chemo before and after surgery (FLOT) versus giving chemo after surgery (XELOX). It’s meant to see which plan works better and is easier to tolerate for locally advanced disease that has not spread.
Hong KongAges 18 years+ - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05281406RecruitingPhase 2
Extra chemotherapy if tumor DNA stays positive after osimertinib
This Phase 2 trial tests whether adding chemotherapy can help people with EGFR-mutated lung cancer when their cancer-related blood test (liquid biopsy for EGFR DNA) is still positive after 3–4 weeks of starting osimertinib. It may help slow the cancer for longer by treating any remaining disease activity.
BerlinAges 18 years+ - NCT05293470Recruiting
Tracking the real-world effects of Piqray in Korea
This study monitors how well and how safely Piqray works for people in Korea in routine care. You may be invited if your breast cancer matches specific genetic and receptor test results and you are starting Piqray for the first time.
Cheonan Si, Chungcheongnam-doAges 18–100 - NCT05315700RecruitingPhase 1/Phase 2
ORIC-114 for advanced lung or breast cancers with EGFR or HER2 changes
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
Duarte, CaliforniaAges 18 years+ - NCT05317819RecruitingPhase 3
Test ADI-PEG 20 versus placebo for advanced liver cancer
This study tests whether ADI-PEG 20 helps people with advanced, unresectable hepatocellular carcinoma (liver cancer) who have high arginine levels. Participants get ADI-PEG 20 or a placebo to see which works better and improves outcomes.
ChanghuaAges 18–99 - NCT05321134Recruiting
Testing single-port robot surgery for colorectal conditions
This study checks how well a newer single-opening (single-port) robot works for colorectal surgery. It may help surgeons perform operations with the robotic system in carefully selected colorectal conditions.
Sacramento, CaliforniaAges 18 years+ - NCT05342194RecruitingPhase 3
Testing an immunotherapy plus chemo for advanced bile duct cancer
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05376592Recruiting
Study genes and weight loss in pancreatic cancer
This study looks at how a person’s genetic variations may relate to cancer-related weight loss (cachexia) in pancreatic cancer. It may help researchers better understand who is most at risk and guide future treatments.
Charlotte, North CarolinaAges 18 years+ - NCT05392413Recruiting
Predicting who benefits from PD-1 antibody for esophageal cancer
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
GuangzhouAges 18–75 - NCT05423262RecruitingPhase 1/Phase 2
TRK-950 for advanced solid tumors that standard treatment can’t control
This trial tests TRK-950 in people with advanced (locally advanced or metastatic) solid tumors when standard treatments have stopped working or aren’t available. It may help by trying a new treatment approach when current options are limited.
Nagoya, Aichi-kenAges 18 years+ - NCT05431738Recruiting
Anti-migration stent for swallowing blockage from reflux cancer
This trial studies a special anti-migration stent placed in the esophagus to help keep a tumor-related blockage open and reduce reflux-related problems. It’s for adults whose swallowing is difficult because of a cancer narrowing at the esophagus-stomach junction.
ParisAges 18–91 - NCT05431595RecruitingPhase 2/Phase 3
Test a less sedating plan for agitated delirium in cancer
This study looks at whether using certain sleep/behavior medicines (called neuroleptics) with anti-seizure medicines can calm agitation from delirium without needing as much of the usual “neuroleptic” medicines. It may help people with advanced cancer who are confused and very restless or hard to settle.
Houston, TexasAges 18 years+ - NCT05448833Recruiting
Testing a wireless sensor to monitor left heart pressure
This study tests whether a small wireless sensor can safely measure and track pressure in the left upper heart chamber in people with advanced chronic heart failure. It may help the care team better understand pressure changes that are linked to fluid buildup and symptoms, alongside your usual heart medicines.
Petah TikvaAges 22–88 - NCT05526989RecruitingPhase 2
Dostarlimab plus niraparib for advanced penile cancer
This Phase 2 study tests whether combining dostarlimab (an immunotherapy) with niraparib (a cancer pill) can shrink advanced penile cancer and keep it from growing. It may help people whose cancer has progressed after limited prior treatments, and who have not had certain immune therapies before.
Tampa, FloridaAges 18 years+ - NCT05528952RecruitingPhase 2
Vaccine plus immunotherapy for unresectable liver cancer
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
BesançonAges 18 years+ - NCT05539196Recruiting
Registry for Exablate treatment in Parkinson’s with medication problems
This trial is a real-world registry that follows people with Parkinson’s who are planning to get an Exablate 4000 procedure (a focused ultrasound treatment) for one-sided symptoms that are difficult to control with medication. It mainly checks outcomes and safety over time, helping doctors understand how well this treatment works in everyday care.
Baltimore, MarylandAges 30–99 - NCT05554003RecruitingPhase 2
Low-grade neuroendocrine tumors: metronomic temozolomide for frail patients
This Phase 2 study tests a gentler, steady schedule of temozolomide in people with advanced low-grade neuroendocrine neoplasms who are “unfit” for stronger treatments. The goal is to shrink or control the cancer while being safer for people with weaker health or organ function.
MilanAges 18 years+ - NCT05570422RecruitingPhase 1
Safety and early benefits of an injection plus radiation for cervical cancer
This Phase 1 study tests whether KRC-01, given by injection into the tumor, is safe and tolerable when combined with standard chemoradiation for locally advanced cervical cancer. It also looks for early signs that the treatment can shrink tumors.
ChandigarhAges 18 years+ - NCT05607498RecruitingPhase 1
First study of EMB-07 for advanced cancers or lymphoma
This Phase 1 trial tests EMB-07, a new treatment, in people with advanced or hard-to-treat solid tumors or certain relapsed/refractory lymphomas. The goal is to find a safe dose and learn whether it can shrink tumors.
Frankston, VictoriaAges 18 years+ - NCT05614739RecruitingPhase 1
Study drug for cancers with an FGFR3 gene change
This Phase 1 trial tests LOXO-435 in people with solid tumors that have an FGFR3 pathway gene alteration. It may help shrink or control cancer by targeting this specific gene change.
Tucson, ArizonaAges 18 years+ - NCT05617456Recruiting
Test new ablation technology for treating irregular heart rhythm
This study tests advanced technology to improve how atrial fibrillation (AFib) is treated with a heart ablation procedure. It may help patients who are already advised to have AFib ablation by seeing how well the approach works in real clinical practice.
PisaAges Any age - NCT05640609RecruitingPhase 1/Phase 2
Stomach cancer study using chemo plus immunotherapy plus targeted drug
This Phase 1/2 trial tests a combination treatment for advanced or metastatic stomach and food-pipe (gastroesophageal junction) cancer: a chemotherapy regimen (CapeOX) plus the immunotherapy drug sintilimab and the targeted drug bevacizumab. It aims to see how well this combination controls the cancer and how safely it can be given.
ChengduAges 18–70 - NCT05652920RecruitingPhase 1/Phase 2
CAR T-cell therapy for liver cancer that has GPC3
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–70
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,559 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.